Literature DB >> 35119617

Phosphaturic Mesenchymal Tumors in the Head and Neck Demonstrate a Broad Clinical and Morphologic Spectrum.

K R Hulme1, A Mahar2, R G Campbell3,4,5, R Clifton-Bligh6,7, A J Gill7,8, C E Palme7,9,10, R Gupta2,7.   

Abstract

Phosphaturic mesenchymal tumour (PMT) is a rare tumour that occurs in bone or soft tissue and is associated with production of fibroblast growth factor 23 (FGF23) leading to tumor-induced osteomalacia. We report three cases of PMT involving the head and neck that highlight the broad spectrum of clinical and histologic features of PMT. One of these lesions from the hard palate demonstrated an admixture of epithelial and mesenchymal elements, a feature that can pose a diagnostic challenge. The diagnostic utility of immunohistochemistry including FGF23, somatostatin receptor 2A, SATB2, ERG and CD56 is discussed. The biochemical pathway in the development of PMT associated tumor induced osteomalacia and its role in investigations and management of PMT is also described.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ERG; Epithelial component in phosphaturic mesenchymal tumor; FGF23; Phosphaturic mesenchymal tumor; SATB2; SSTR2A; Tumor-induced osteomalacia

Mesh:

Substances:

Year:  2022        PMID: 35119617      PMCID: PMC9424444          DOI: 10.1007/s12105-022-01419-8

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  1 in total

1.  CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.